Evidence map›Paper›PMID 39503319›Full record

ReviewAnnals of neurology2024

The Scientific and Therapeutic Rationale for Off-Label Treatments in Amyotrophic Lateral Sclerosis.

Richard Bedlack, Xiaoyan Li, Baggio Angelo Evangelista, Maria E Panzetta, Justin Kwan, Lauren M Gittings, Rita Sattler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Richard BedlackDuke University Department of Neurology, Durham, NC, USA.ORCID https://orcid.org/0000-0003-4666-7495
Xiaoyan LiDuke University Department of Neurology, Durham, NC, USA.
Baggio Angelo EvangelistaUniversity of North Carolina Department of Neurology, Chapel Hill, NC, USA.
Maria E PanzettaDuke University Department of Integrative Immunobiology, Durham, NC, USA.
Justin KwanNeurodegeneration Disorders Clinic, National Institute of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-1558-4451
Lauren M GittingsDepartment of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, USA.
Rita SattlerDepartment of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, USA.

Funding

ALS Association
6 · The paper itself

Abstract

There are no dramatically effective pharmacological treatments for most patients with amyotrophic lateral sclerosis, a complex disease with multiple underlying mechanisms, such as neuroinflammation, oxidative stress, mitochondrial dysfunction, microbiome alteration, and antiretroviral activity. We sifted through 15 years of reviews by a group called ALSUntangled to identify 8 alternative and off-label treatments that target ≥1 of these mechanisms, and have ≥1 human trial suggesting meaningful benefits. Given the overlapping pathological mechanisms of the highlighted products, we suggest that combinations of these treatments targeting diverse mechanisms might be worthwhile for future amyotrophic lateral sclerosis therapy development. ANN NEUROL 2024.

Identifiers

PMID39503319
PMCPMC11683184

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.